Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Conditions

• Ovarian Clear Cell Adenocarcinoma
• Platinum-Sensitive Ovarian Carcinoma
• Recurrent Endometrial Serous Adenocarcinoma
• Recurrent Fallopian Tube Carcinoma
• Recurrent Fallopian Tube Endometrioid Adenocarcinoma
• Recurrent Fallopian Tube Serous Adenocarcinoma
• Recurrent Ovarian Carcinoma
• Recurrent Ovarian Clear Cell Adenocarcinoma
• Recurrent Ovarian Endometrioid Adenocarcinoma
• Recurrent Ovarian Serous Adenocarcinoma
• Recurrent Platinum-Resistant Ovarian Carcinoma
• Recurrent Primary Peritoneal Carcinoma
• Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
• Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
• Recurrent Primary Peritoneal Serous Adenocarcinoma

Interventions

• BIOLOGICAL: Anti-CD40 Agonist Monoclonal Antibody CDX-1140
• BIOLOGICAL: Bevacizumab
• BIOLOGICAL: Pembrolizumab
• OTHER: Quality-of-Life Assessment
• OTHER: Questionnaire Administration

Sponsor

Roswell Park Cancer Institute

Collaborators

• [object Object]
• [object Object]
• [object Object]